ORIGINAL INVESTIGATION
|
|
- Jeremy Marshall
- 6 years ago
- Views:
Transcription
1 Total Cholesterol/HDL Cholesterol Ratio vs LDL Cholesterol/HDL Cholesterol Ratio as Indices of Ischemic Heart Disease Risk in Men The Quebec Cardiovascular Study ORIGINAL INVESTIGATION Isabelle Lemieux, MSc; Benoît Lamarche, PhD; Charles Couillard, PhD; Agnès Pascot, MSc; Bernard Cantin, MD, PhD; Jean Bergeron, MD, MSc; Gilles R. Dagenais, MD; Jean-Pierre Després, PhD Background: Total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C)/HDL-C ratios are used to predict ischemic heart disease risk. There is, however, no consensus on which of these indices is superior. The objective of the present study was to present evidence that the LDL-C/HDL-C ratio may underestimate ischemic heart disease risk in overweight hyperinsulinemic patients with high triglyceride (TG) low HDL-C dyslipidemia. Methods: A total of 13 middle-aged men in whom measurements of the metabolic profile were performed in the fasting state were recruited from 7 suburbs of the Quebec metropolitan area. Results: The relationship of LDL-C/HDL-C to TC/ HDL-C ratios was examined among men in the Quebec Cardiovascular Study classified into tertiles of fasting TG levels. For any given LDL-C/HDL-C ratio, the TC/ HDL-C ratio was higher among men in the top TG tertile ( 1 mg/dl [ 1.9 mmol/l]) than in men in the first and second TG tertiles. Adjustment of the TC/ HDL-C ratio for LDL-C/HDL-C by covariance analysis generated significant differences in average TC/HDL-C ratios among TG tertiles (P.1). Greater differences in features of the insulin resistance syndrome (insulinemia, apolipoprotein B, and LDL size) were noted across tertiles of the TC/HDL-C ratio than tertiles of the LDL- C/HDL-C ratio. Conclusion: Variation in the TC/HDL-C ratio may be associated with more substantial alterations in metabolic indices predictive of ischemic heart disease risk and related to the insulin resistance syndrome than variation in the LDL-C/HDL-C ratio. Arch Intern Med. 1;11:5-9 From the Quebec Heart Institute, Laval Hospital Research Center Mss Lemieux and Pascot and Drs Couillard, Cantin, Dagenais, Després), and the Lipid Research Center, CHUL Research Center (CHUQ) (Drs Lamarche, Couillard, Cantin, Bergeron, and Després and Mss Lemieux and Pascot), Sainte-Foy, Quebec. DESPITE considerable advances during the past years, there is increasing awareness among scientists, epidemiologists, and clinicians that current approaches to evaluation of coronary heart disease (CHD) risk in asymptomatic individuals remain suboptimal. 1 There is also controversy around recommending widespread use of additional metabolic markers, such as apolipoprotein (APO) levels, indices of fibrinolytic activity and of susceptibility to thrombosis (eg, plasminogen activator inhibitor 1 and lipoprotein[a] levels), markers of inflammation (eg, C-reactive protein levels), and markers of insulin resistance (waist circumference and fasting insulin levels). -9 Although all of these markers have been shown to predict CHD events, whether these variables contribute to CHD risk independently of the variation in traditional risk factors and lipid variables remains a matter of debate. Regarding the traditional fasting plasma lipid profile (triglycerides [TGs], total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C] [which is most often calculated rather than measured directly], and high-density lipoprotein cholesterol [HDL-C]), there is no universal acceptance of how this information should be used and interpreted, although several consensus documents have been produced.,1-13 Because there is overwhelming evidence 1,15 that an elevated LDL-C concentration in plasma is atherogenic, whereas a high HDL-C level is cardioprotective, the measurement and interpretation of LDL-C and HDL-C levels is emphasized in the US National Cholesterol Education Program guidelines. 11 According to these guidelines, 11 LDL-C concentration should be considered the primary (REPRINTED) ARCH INTERN MED/ VOL 11, DEC 1/, American Medical Association. All rights reserved. Downloaded From: on 1//1
2 PARTICIPANTS AND METHODS THE QUEBEC CARDIOVASCULAR STUDY The population and evaluation procedures of the Quebec Cardiovascular Study have been described previously.,3 Briefly, 3 men were evaluated in 195 for IHD risk factors, including familial history of IHD, history of smoking, diabetes mellitus, blood pressure measurement, height and weight, determination of the fasting plasma lipid and lipoprotein profile, and an electrocardiogram. Each participant completed a standardized questionnaire administered by trained nurses. After exclusion of men with fasting TG levels greater than 399 mg/dl (.5 mmol/l) and patients with clinical signs of IHD, 13 middle-aged men who were asymptomatic for IHD were followed for 5 years for the occurrence of IHD events. During this period, 11 men developed a first ischemic event, which included typical effort angina, coronary insufficiency, nonfatal myocardial infarction, and coronary death. Logistic regression analysis using the Cox proportional hazards model revealed that diabetes mellitus, LDL-C level, age, systolic blood pressure, HDL-C level, smoking, and medication use at baseline ( -adrenergic blocking agents and diuretics) were the best independent predictors of IHD in this cohort. 5 LABORATORY ANALYSES After participants had fasted for 1 hours, blood samples were obtained from an antecubital vein while participants were sitting. A tourniquet was used, but it was released before withdrawal of blood into Vacutainer tubes (Becton Dickinson, Mountain View, Calif) containing EDTA. Plasma was separated from blood cells by centrifugation and immediately used for measurement of lipoproteinlipid and APOB levels. Aliquots of fasting plasma were frozen at the time of collection for subsequent assessment of insulin levels. Plasma TC and TG concentrations were determined using a Technicon RA-5 analyzer (Bayer Corp, Tarrytown, NY), as previously described. The HDL-C level was measured in the supernatant after precipitation of APOBcontaining lipoproteins with heparin manganese chloride. 7 The LDL-C concentration was estimated using the equation of Friedewald et al because men with TG concentrations greater than 399 mg/dl (.5 mmol/l) were excluded from the analyses. Plasma APOB concentrations were measured using the rocket immunoelectrophoretic method of Laurell, 9 as previously described. Serum standards for the APOB assay were prepared in our laboratory (Lipid Research Center, Sainte-Foy, Quebec) and calibrated against serum samples obtained from the Centers for Disease Control and Prevention (Atlanta, Ga). The standards were lyophilized and stored at C until use. The coefficients of variation for TC, HDL-C, and TG levels were all less than 3%, and for APOB measurements were less than 5%. Fasting insulin concentrations were measured using a commercial double-antibody radioimmunoassay (human insulin specific radioimmunoassay method; LINCO Research, St Louis, Mo). This insulin assay shows little crossreactivity with human proinsulin (.%). 3 The coefficients of variation were 3.5% for lower insulin concentrations and 5.% for higher concentrations. The LDL peak particle diameter was obtained from the nondenaturing % to 1% polyacrylamide gel electrophoresis of whole plasma, which was kept at C before use, according to the procedure described by Krauss and Burke 31 and by McNamara et al. 3 Gels were cast in our laboratory using acrylamide and bisacrylamide (3.:.) obtained from Bio-Rad (Hercules, Calif). A volume of 7.5 µl of plasma samples was applied on lanes in a final concentration of % sucrose and.5% bromophenol blue. Electrophoresis was performed in a refrigerated cell (1 C-15 C) for a prerun of 15 minutes at 15 V and for the entry of samples into stacking at 7 V, followed by migration at V for 1 to 1 hours and finally at V for to hours. Gels were stained for lipids overnight with sudan black (Lipostain, Paragon electrophoresis system; Beckman, Montreal, Quebec) in 55% ethanol. Gels were destained in a 5% ethanol solution, and original gel size was restored in a 9% acetic acid, % methanol solution. A plasma pool was used as an internal standard. Gels were analyzed using an optical densitometer image analyzer (Bio-Image Visage 11) coupled to a SPARC Station Sun computer (Millipore, Ville St-Laurent, Quebec) and using GEL 1D software. Low-density lipoprotein peak particle size was obtained using the migration of standards of known diameter, such as ferritin (1 Å), thyroglobulin (17 Å), and 3-Å latex beads (Duke Scientific Corp, Palo Alto, Calif), and plasma standards of known diameter. Analyses of pooled plasma standards revealed that identification of the major LDL peak was highly reproducible, with an interassay coefficient of variation of less than 3% (B. Lamarche, PhD, A. Tchernof, PhD, S. Moorjani, PhD, et al, unpublished data, 1997). STATISTICAL PROCEDURES All analyses were conducted using the SAS statistical computer program package (SAS Institute, Cary, NC). Prevalence odds ratios for quintiles of the LDL-C/HDL-C or TC/HDL-C ratios were assessed using logistic regression procedures. Group differences for continuous variables were examined using either the t test or the general linear model, and the Duncan post-hoc test was used in situations in which a significant group effect was observed. Pearson product moment correlation coefficients were used to quantify associations between variables. Statistical adjustment of data was performed using the general linear model procedure, with adjustment for the LDL-C/ HDL-C ratio. therapeutic target, whereas HDL-C levels may also be critical in the assessment of CHD risk. Thus, because TG levels are ignored in the National Cholesterol Education Program algorithm, the clinician is left with LDL-C and HDL-C levels to assess risk while considering the presence or absence of other important risk factors, such as family history of early CHD, age, smoking, hypertension, diabetes mellitus, low physical activity, and obesity. On this basis, the LDL-C/HDL-C ratio is often calculated to estimate CHD risk. Results of prospective studies 1,19 have suggested that a high LDL-C/HDL-C ratio combined with hypertriglyceridemia is associated with highest CHD risk. Thus, algorithms have been produced showing that an elevated (REPRINTED) ARCH INTERN MED/ VOL 11, DEC 1/, 1 1 American Medical Association. All rights reserved. Downloaded From: on 1//1
3 Table 1. Characteristics of 11 Men in the Quebec Cardiovascular Study Who Developed IHD Compared With 199 Men Who Remained IHD Free During 5-Year Follow-up A 3. (P<.1) 3.7 (P<.1) Variable Without IHD (n = 199) With IHD (n = 11) P Value Age, y 5 ± 7 59 ±.1 Body mass index ± 7 ±.7 Diabetes, % 1.1 Smokers, % 3.7 Systolic blood pressure, mm Hg 13 ± ± 17.1 Diastolic blood pressure, mm Hg 1 ± 1 ± 1.7 Triglycerides, mg/dl 15 ± 177 ±.1 Total cholesterol, mg/dl ± 3 35 ± 1.1 LDL-C, mg/dl 19 ± 35 1 ± 37.1 HDL-C, mg/dl ± 1 37 ± 9.1 Apolipoprotein B, mg/dl 1.1 ± ±.3.1 Total cholesterol/hdl-c ratio 5.1 ± 1..7 ± LDL-C/HDL-C ratio 3.9 ± ± Data are given as mean ± SD, except where indicated otherwise. IHD indicates ischemic heart disease; LDL-C, low-density lipoprotein cholesterol; and HDL-C, high-density lipoprotein cholesterol. Calculated as weight in kilograms divided by the square of height in meters. To convert triglycerides from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by.119. To convert total, LDL, and HDL cholesterol from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by.5. IHD Odds Ratio IHD Odds Ratio B 1..9 (1) () 3. (3) Quintiles of LDL-C/HDL-C Ratio.. (P<.).5 () 3. (P<.).1 (5).1 (P<.1) LDL-C/HDL-C ratio combined with elevated TG is associated with high CHD risk. This dyslipidemic state (lipid triad) has been described as atherogenic dyslipidemia. We believe that this approach could be further simplified by using the TC/HDL-C ratio. Because there is more cholesterol in the very LDL (VLDL) fraction in individuals with elevated TG concentrations, the LDL-C/HDL-C ratio may underestimate the magnitude of the dyslipidemic state in these patients. On that basis, we propose that the high prevalence of moderate hypertriglyceridemia among patients with CHD explains why the TC/ HDL-C ratio was the best predictor of ischemic heart disease (IHD) risk in several observational prospective studies, including the Quebec Cardiovascular Study. 5 However, reduction of this ratio and of the LDL-C/ HDL-C ratio in patients initially free of IHD who were treated with a lipid-lowering drug (lovastatin) was found to predict a decreased risk of a first IHD event. 1 Therefore, the objective of this article was to present evidence from the Quebec Cardiovascular Study that supports the notion that the TC/HDL-C ratio may be a better and simpler cumulative marker of the presence of atherogenic dyslipidemia and of increased IHD risk than the LDL-C/HDL-C ratio. RESULTS Table 1 gives the baseline characteristics of the 11 men who developed IHD compared with those who remained IHD free during 5-year follow-up. Overall, men with IHD were characterized by an unfavorable metabolic profile compared with asymptomatic men. When the TC/HDL-C ratio was included in a multivariate model, it was found to be the best single predictor of IHD risk (1).5 () in the Quebec Cardiovascular Study. 5 Neither TG nor HDL-C levels further contributed to IHD risk once the TC/HDL-C ratio had been considered in the analysis. These observations are concordant with results from the Copenhagen Male Study, 33 where it was found that after adjustment for age and nonlipid risk factors, the TC/ HDL-C ratio was the strongest predictor of IHD risk. Results presented in Figure 1 indicate that there was a progressive increase in the IHD odds ratio across quintiles of the TC/HDL-C ratio, whereas only men in quintiles and 5 of the LDL-C/HDL-C ratio were characterized by increased IHD risk. We believe that there is a metabolic rationale underlying this finding. It is well documented that high TG low HDL-C dyslipidemia, which is often linked to abdominal obesity and insulin resistance, is associated with marginal or even no change in LDL-C levels. 3 Furthermore, LDL-C concentrations are often estimated from 3 measurements (TG, TC, and HDL-C) rather than measured directly. Thus, a variation that may reach 5% in estimated LDL-C levels could be explained by these 3 components. 35 This variation may therefore have a major effect on the calculated LDL-C/ HDL-C ratio. On the other hand, the components of 5.7 (3) Quintiles of TC/HDL-C Ratio Figure 1. Odds ratios for ischemic heart disease (IHD) during 5-year follow-up in 13 men in the Quebec Cardiovascular Study classified according to quintiles of low-density lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) (A) and total cholesterol (TC)/HDL-C (B) ratios. Numbers below the bars indicate the mean LDL-C/HDL-C or TC/HDL-C ratios for each quintile, whereas numbers above the bars indicate the relative odds ratio compared with the first quintile..5 (). (5) (REPRINTED) ARCH INTERN MED/ VOL 11, DEC 1/, American Medical Association. All rights reserved. Downloaded From: on 1//1
4 Table. Characteristics of 1 Men in the Quebec Cardiovascular Study Classified on the Basis of TG and HDL-C Levels Variable Normolipidemic Men (n = 117) High TG Low HDL-C Dyslipidemic Men (n = 99) Age, y 5. ± ± 7. Body mass index 5.3 ± ± 3. Total cholesterol, mg/dl 17±3 7±39 TG, mg/dl# 11 ± 31 ± 53 LDL-C, mg/dl 19±3 19±3 HDL-C, mg/dl 5±9 9± Total cholesterol/hdl-c ratio.9 ± ± 1.59 LDL-C/HDL-C ratio 3.1 ± ± 1.5 Apolipoprotein B, mg/dl 1 ± 135 ± 3 Fasting insulin, µu/ml 1±5 13± Event rate, % Data are given as mean ± SD, except where indicated otherwise. TG indicates triglyceride; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol. TG 177 mg/dl (. mmol/l) and HDL-C 35 mg/dl (.9 mmol/l). TG 177 mg/dl (. mmol/l) and HDL-C 35 mg/dl (.9 mmol/l). Calculated as weight in kilograms divided by the square of height in meters. P.1. To convert total, LDL, and HDL cholesterol from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by.5. #To convert TG from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by.119. To convert insulin from microunits per milliliter to picomoles per liter, multiply microunits per milliliter by.95. P.5. Body Mass Index Insulin, µu/ml TC/HDL-C Ratio LDL-C/HDL-C Ratio 1 VLDL 19 LDL 151 HDL Normolipidemic Men (n = 117) 5.3 ± 3. 1 ±.9 ± ± 1. = VLDL LDL 151 HDL 31 High TG Low HDL-C Dyslipidemic Men (n = 99) Difference, % 7. ± 3. 1 ± ± ± 1.5 Total Cholesterol, mg/dl 5 Figure. Relative differences in the total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C)/HDL-C ratios between normolipidemic men and men of the Quebec Cardiovascular Study with high triglyceride (TG) low HDL-C dyslipidemia. VLDL indicates very low-density lipoprotein; ellipses, not applicable. To convert cholesterol from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by.5. To convert insulin from microunits per milliliter to picomoles per liter, multiply microunits per milliliter by.95. Body mass index is calculated as weight in kilograms divided by the square of height in meters. the TC/HDL-C ratio are measured directly, and this ratio can be used in men with TG levels greater than 399 mg/dl (.5 mmol/l). As given in Table, men in the Quebec Cardiovascular Study with high TG low HDL-C dyslipidemia (TG, 177 mg/dl [. mmol/l]; and HDL-C, 35 mg/dl [.9 mmol/l]) were characterized by a higher body mass index (calculated as weight in kilograms divided by the square of height in meters) and by elevated fasting insulin concentrations compared with normolipidemic men despite identical LDL-C levels in the groups. Moreover, the IHD event rate was times higher among these men. Thus, when the LDL-C/HDL-C ratio was computed in these overweight hyperinsulinemic patients with high TG low HDL-C dyslipidemia, its increase resulted only from the reduced HDL-C levels associated with this condition (Figure ). However, the increased TC/HDL-C ratio obtained in overweight hyperinsulinemic men with high TG low HDL-C dyslipidemia not only resulted from the decreased HDL-C level but also from the slight increase in the TC level as more TC was associated with the calculated VLDL fraction in hypertriglyceridemic individuals than in normolipidemic men (Figure ). Thus, the relative difference in the TC/HDL-C ratio in overweight patients with high TG low HDL-C dyslipidemia vs normotriglyceridemic men (%) was greater than the difference in the LDL-C/HDL-C ratio between these groups (5%). This phenomenon is further illustrated in Figure 3, in which participants in the Quebec Cardiovascular Study were stratified into tertiles of fasting TG levels. In all TG tertiles, significant correlations were observed between LDL- C/HDL-C and TC/HDL-C ratios (r=1.,.99, and.9 in the 3 TG tertiles, respectively; P.1), a finding that would, at first glance, suggest that both ratios essentially provide similar information. However, the intercept of the relationship between the ratios was different among the 3 TG tertiles. Thus, among men in the top TG tertile (TG, 1 mg/dl [ 1.9 mmol/l]), higher TC/HDL-C ratios were found for any given LDL-C/HDL-C value than in the other tertiles. Accordingly, results in Figure indicate that the difference in the TC/HDL-C ratio in the top tertile vs the first tertile of fasting TG levels was greater than the difference in the LDL-C/HDL-C ratio. Our results are in accordance with those of Leroux et al, 3 who demonstrated that the relative cholesterol content of the calculated VLDL fraction increased across TG quintiles, whereas there was also relatively less cholesterol associated with the HDL fraction as a function of increasing triglyceridemia. Moreover, a study conducted by McNamara et al 37 demonstrated that the difference between the estimated LDL-C concentrations and values obtained by measuring cholesterol in the LDL fraction isolated by ultracentrifugation was substantially greater in hypertriglyceridemic individuals than in those with normal TG levels. To quantify potential differences in the TC/HDL-C ratio and in the risk profile beyond what could be explained by the LDL-C/HDL-C ratio, we adjusted the TC/HDL-C ratio for the concomitant variation in (REPRINTED) ARCH INTERN MED/ VOL 11, DEC 1/, 1 1 American Medical Association. All rights reserved. Downloaded From: on 1//1
5 1 A 1 B TC/HDL-C Ratio 1 1 r =.97; P<.1 T1: TG mg/dl r = 1.; P< C 1 D TC/HDL-C Ratio 1 1 T: TG mg/dl r =.99; P<.1 T3: TG>1 mg/dl r =.9; P< LDL-C/HDL-C Ratio LDL-C/HDL-C Ratio Figure 3. Relationships between the low-density lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) and total cholesterol (TC)/HDL-C ratios among men in the Quebec Cardiovascular Study divided into tertiles of fasting plasma triglyceride (TG) levels. To convert TG from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by % % LDL-C/HDL-C Ratio 3 TC/HDL-C Ratio (1) (31) >1 (1) (31) >1 Figure. Low-density lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) and total cholesterol (TC)/HDL-C ratios according to triglyceride (TG) tertiles in men in the Quebec Cardiovascular Study. Asterisk indicates significantly different from the first tertile; dagger, significantly different from the second tertile (P.1). The relative difference between the third and first tertiles of LDL-C/HDL-C or TC/HDL-C ratios is indicated above the bar. Numbers within parentheses indicate the mean TG level for each tertile. Error bars represent SE. To convert TG from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by.119. (REPRINTED) ARCH INTERN MED/ VOL 11, DEC 1/, American Medical Association. All rights reserved. Downloaded From: on 1//1
6 Table 3. Characteristics of Men in the Quebec Cardiovascular Study Classified on the Basis of Tertiles of TG Levels After Adjustment for LDL-C/HDL-C Ratio by Covariance Analysis Variable 115 (1) (n = ) TG Tertile, mg/dl () (n = 735) 1 (3) (n = 99) Difference, (1) vs (3), % Age, y 5.5 ± ± ± 7.. Body mass index 5. ± ± ± 3.7. TG, mg/dl 93 ± 1 ± 9 ± Total cholesterol, mg/dl 17 ± 3 ± 31 ± 31.1 LDL-C, mg/dl 15 ± 3 15 ± 1 1 ± 31.9 HDL-C, mg/dl ± 7 ± 7 3 ± Total cholesterol/hdl-c ratio 5.9 ± ±.7.33 ± LDL-C/HDL-C ratio Data are given as mean ± SD, except where indicated otherwise. TG indicates triglyceride; LDL-C, low-density lipoprotein cholesterol; and HDL-C, high-density lipoprotein cholesterol. There were, 735, and 97 participants for tertiles 1,, and 3, respectively. Body mass index calculated as weight in kilograms divided by the square of height in meters. Significantly different from tertile (1). Significantly different from tertiles (1) and (). To convert TG from milligrams per deciliter to millimoles per liter, multiply millimoles per deciliter by.119. To convert total, LDL, and HDL cholesterol from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by.5. Apolipoprotein B, mg/dl Fasting Insulin, µu/ml LDL Peak Particle Size, Å 55 5 (1) (31) >1 (1) (31) >1 5 (1) (31) >1 Figure 5. Fasting apolipoprotein B and insulin levels and low-density lipoprotein (LDL) peak particle size among triglyceride (TG) tertiles in men in the Quebec Cardiovascular Study. Asterisk indicates significantly different from the first tertile; dagger, significantly different from the second tertile (P.1). Numbers within parentheses indicate the mean TG level for each tertile. Error bars represent SE. To convert TG from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by.119. To convert insulin from microunits per milliliter to picomoles per liter, multiply microunits per milliliter by.95. LDL-C/HDL-C ratio by covariance analysis (Table 3). Thus, when the TC/HDL-C ratios across TG tertiles were standardized for an LDL-C/HDL-C ratio of 3.99, the first TG tertile (TG, 115 mg/dl [ 1.3 mmol/l]) had an adjusted TC/HDL-C ratio of 5.9, the second TG tertile (TG, mg/dl [ mmol/l]) had a TC/HDL-C ratio of 5.73, whereas the top TG tertile (TG, 1 mg/dl [ 1.9 mmol/l]) had a TC/HDL-C ratio that reached.33. Thus, the results indicate that individuals with similar LDL-C/HDL-C ratios may have markedly different TC/ HDL-C ratios depending on their fasting TG levels. Lamarche et al 3 also previously reported that patients with high TG low HDL-C are characterized by clustering metabolic abnormalities described as the atherogenic metabolic triad of nontraditional risk factors, which included hyperinsulinemia, elevated APOB level, and small, dense LDL particles. Thus, a higher proportion of men with elevated TG levels were also characterized by the features of the atherogenic metabolic triad. Figure 5 shows that men with high TG concentrations had elevated APOB and insulin levels and smaller LDL particles than men characterized by low TG levels. Accordingly, Figure compares these features of the atherogenic metabolic triad (insulin, APOB, and LDL size) across tertiles of TC/HDL-C and LDL-C/HDL-C ratios. There was a progressive increase in plasma APOB (+7 mg/dl; +5%) and insulin (+3 µu/ml [+1.3 pmol/ L]; +3%) levels from the first to the third TC/HDL-C tertiles, which was accompanied by a significant decrease in LDL peak particle size (.5 Å; %). There was also a progressive increase in APOB (+ mg/dl; +5%) and insulin (+ µu/ml [+1.7 pmol/l]; +1%) concentrations and a decrease in LDL peak particle diameter ( 3.5 Å; 1%) in the first vs third tertiles of the LDL- C/HDL-C ratio. However, there was a greater deterioration in of the 3 features of the atherogenic metabolic triad (insulin and LDL size) across TC/HDL-C ratio tertiles than among tertiles of the LDL-C/HDL-C ratio. Therefore, although both LDL-C/HDL-C and TC/HDL-C ratios were significantly correlated with the features of the atherogenic metabolic triad related to the insulin resistance syndrome (hyperinsulinemia, elevated APOB level, and small, dense LDL particles), variation in the TC/HDL-C ratio seems to better reflect underlying metabolic alterations (REPRINTED) ARCH INTERN MED/ VOL 11, DEC 1/, American Medical Association. All rights reserved. Downloaded From: on 1//1
7 LDL Size, Å Fasting Insulin, µu/ml Apolipoprotein B, mg/dl (+5%) + (+5%) +3 (+3%) + (+1%).5 ( %) 3.5 ( 1%) measured, and we propose that, in addition to the wellestablished conventional risk factors, the TC/HDL-C ratio may represent an important cumulative index of the presence of an atherogenic dyslipidemic profile associated with insulin resistance. Because the high TG low HDL-C dyslipidemia associated with small, dense LDL particles has been suggested to represent the most prevalent lipoprotein phenotype among patients with CHD, the importance of measuring and properly interpreting the TC/HDL-C ratio (rather than the LDL-C/HDL-C ratio) is emphasized. In summary, the TC/HDL-C ratio was a useful and simple index of IHD risk in men in the Quebec Cardiovascular Study. It is proposed that the ability of this ratio to predict risk is explained by the fact that it is a relevant cumulative marker of the cluster of metabolic abnormalities found in individuals with high TG low HDL-C dyslipidemia. This condition has been shown to be the consequence of abdominal obesity and insulin resistance and is also commonly associated with an increased concentration of small, dense LDL particles. Because little variation is found in plasma LDL-C levels in overweight hyperinsulinemic men compared with normolipidemic individuals, we propose that calculation of the LDL-C/HDL-C ratio may underestimate IHD risk in some patients compared with the quality of the estimation achieved with the simple use of the TC/HDL-C ratio..13 (1) 5. () TC/HDL-C Tertiles 7.75 (3) in the features of the insulin resistance syndrome than the LDL-C/HDL-C ratio. COMMENT An elevated TC/HDL-C ratio in men is observed among overweight, hyperinsulinemic, and hypertriglyceridemic individuals. Additional metabolic alterations found in these individuals include, among others, elevated APOB levels, an exaggerated postprandial lipemia, and small, dense LDL particles Results of the present study suggest that these atherogenic metabolic disturbances may not always be adequately reflected by the variation in the LDL-C/HDL-C ratio. In the Quebec Cardiovascular Study, Lamarche et al 3 previously reported that variables such as APOB and fasting insulin levels and LDL size could provide a more refined evaluation of IHD risk than traditional lipid variables. In clinical practice, however, these markers are not.1 (1) 3. () LDL-C/HDL-C Tertiles Figure. Fasting apolipoprotein B and insulin levels and low-density lipoprotein (LDL) peak particle size among tertiles of total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C) or LDL-C/HDL-C ratios in men in the Quebec Cardiovascular Study. Asterisk indicates significantly different from the first tertile; dagger, significantly different from the second tertile (P.5). The absolute and relative differences between the top and first tertiles of TC/HDL-C or LDL-C/HDL-C ratios are indicated above the bars. Numbers below the bars indicate the mean TC/HDL-C or LDL-C/HDL-C ratios for each tertile. Error bars represent SE. To convert insulin from microunits per milliliter to picomoles per liter, multiply microunits per milliliter by (3) Accepted for publication April 1, 1. This study was supported in part by the Canadian Institutes of Health Research, the Quebec Heart and Stroke Foundation, and an unrestricted grant from Fournier Pharma Inc, Montreal, Quebec. Dr Després is chair professor of human nutrition and lipidology, which is supported by Pfizer, Provigo, and the Foundation of the Quebec Heart Institute. Dr Lamarche is chair professor at Laval University. Ms Lemieux is a research fellow of the Heart and Stroke Foundation of Canada. Dr Bergeron is a clinical research scholar from the Fonds de la Recherche en Santé du Québec. Corresponding author and reprints: Jean-Pierre Després, PhD, Quebec Heart Institute, Laval Hospital Research Center, 75, chemin Sainte-Foy, Pavilion Mallet, Second Floor, Sainte-Foy, Quebec, Canada G1V G5 ( jean-pierre.despres@crchul.ulaval.ca). REFERENCES 1. Superko HR. The new thinking on lipids and coronary artery disease. Curr Opin Cardiol. 1997;1: Assmann G, Cullen P, Jossa F, Lewis B, Mancini M, for the International Task Force for the Prevention of Coronary Heart Disease. Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease: a worldwide view. Arterioscler Thromb Vasc Biol. 1999;19: Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 19 to 199. Circulation. 1999;99:37-.. Sniderman AD, Genest JJ. The measurement of apolipoprotein B should replace the conventional lipid profile in screening for cardiovascular risk. Can J Cardiol. 199;: Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec Cardiovascular Study. Circulation. 199;9:73-7. (REPRINTED) ARCH INTERN MED/ VOL 11, DEC 1/, American Medical Association. All rights reserved. Downloaded From: on 1//1
8 . Juhan Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;3: Després JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 199;33: Lemieux S, Prud homme D, Bouchard C, Tremblay A, Després JP. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr. 199;: Cantin B, Gagnon F, Moorjani S, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? the Quebec Cardiovascular Study. JAm Coll Cardiol. 199;31: Final report: Canadian Consensus Conference on the prevention of heart and vascular disease by altering serum cholesterol and lipoprotein risk factors. CMAJ. 19;139: National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 199;9: Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart. 199;:S1-S Fodor JG, Frohlich JJ, Genest JJ Jr, McPherson PR. Recommendations for the management and treatment of dyslipidemia: report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ. ;1: Kannel WB, Neaton JD, Wenworth D, et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 35,3 men screened for the MRFIT. Am Heart J. 19;11: Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 19;5: Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med. 1977;: Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet. 1977;1: Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 199;19(suppl M):M-M Manninen V, Tenkanen L, Koshinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 199; 5: Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95: Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 199;79: Dagenais GR, Robitaille NM, Lupien PJ, et al. First coronary heart disease event rates in relation to major risk factors: Québec Cardiovascular Study. Can J Cardiol. 199;: Lamarche B, Després JP, Moorjani M, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study). Am J Cardiol. 1995;75: Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J. 19;1: Després JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Québec Cardiovascular Study. Atherosclerosis. ;153:3-7.. Moorjani S, Dupont A, Labrie F, et al. Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 197;3: Albers JJ, Warnick GR, Wiebe D, et al. Multi-laboratory comparison of three heparin- MnCl precipitation procedures for estimating cholesterol in high-density lipoproteins. Clin Chem. 197;: Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 197;1: Laurell CB. Electroimmunoassay. Scand J Clin Lab Med. 197;1: Orchard TJ, Becker DJ, Bates M, Kuller LH, Drash AL. Plasma insulin and lipoprotein concentrations: an atherogenic association? Am J Epidemiol. 193;11: Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 19;3: McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 197;7: Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease: an -year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol. 1997;17: Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease: results from the Québec Cardiovascular Study. Atherosclerosis. 199;119: Schectman G, Sasse E. Variability of lipid measurements: relevance for the clinician. Clin Chem. 1993;39: Leroux G, Lemieux I, Lamarche B, et al. Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels. Metabolism. ;9: McNamara JR, Cohn JS, Wilson PW, Schaefer EJ. Calculated values for lowdensity lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem. 199;3: Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 199;79: Couillard C, Bergeron N, Prud homme D, et al. Postprandial triglyceride response in visceral obesity in men. Diabetes. 199;7: Tchernof A, Lamarche B, Prud homme D, et al. The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care. 199;19: Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapob, small, dense LDL) in men? Circulation. ;1: Björntorp P. Abdominal obesity and the metabolic syndrome. Ann Med. 199; : Després JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition. 1993;9: Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 199; :95-5. (REPRINTED) ARCH INTERN MED/ VOL 11, DEC 1/, American Medical Association. All rights reserved. Downloaded From: on 1//1
Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart Disease
Original Contributions Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart Disease Benoît Lamarche, PhD; André Tchernof, PhD; Pascale
More informationKatsuyuki Nakajima, PhD. Member of JCCLS International Committee
Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham
More informationThe importance of both low-density lipoprotein
Improving the Prediction of Cardiovascular Risk: Interaction Between LDL and HDL Cholesterol Steven A. Grover, 1,2,3,4 Marc Dorais, 1,3 and Louis Coupal 1,3 Background. The ratio of total cholesterol to
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Age and Duration of Follow-up as Modulators of the Risk for Ischemic Heart Disease Associated With High Plasma C-Reactive Protein Levels in Men Matteo Pirro, MD; Jean Bergeron, MD;
More informationReduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity
Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity Agnès Pascot,*, Isabelle Lemieux,*, Denis Prud homme, Angelo Tremblay, André Nadeau,** Charles Couillard,*
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationApolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.13 Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationHigh Density Lipoprotein Cholesterol and Mortality
High Density Lipoprotein Cholesterol and Mortality The Framingham Heart Study Peter W.F. Wilson, Robert D. Abbott, and William P. Castelli In 12 years of follow-up for 2748 Framingham Heart Study participants
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationRecently reported clinical trials have provided strong
Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions The Atherosclerosis Risk in Communities (ARIC)
More informationLipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease
Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO;
More informationEffects of Endurance Exercise Training on Plasma HDL Cholesterol Levels Depend on Levels of Triglycerides
Effects of Endurance Exercise Training on Plasma HDL Cholesterol Levels Depend on Levels of Triglycerides Evidence From Men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family
More informationLipoprotein (a): Is it important for Friedewald formula?
ORIGINAL RESEARCH ALBANIAN MEDICAL JOURNAL Lipoprotein (a): Is it important for Friedewald formula? Murat Can 1, Berrak Guven 1 1 Bulent Ecevit University, Faculty of Medicine, Department of Biochemistry
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients
ARTICLE Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients Baruch S. Ticho, MD, PhD; Ellis J. Neufeld, MD, PhD; Jane W. Newburger, MD, MPH; Neil Harris,
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationContribution of Visceral Adiposity to the Exaggerated Postprandial Lipemia of Men With Impaired Glucose Tolerance
Pathophysiology/Complications O R I G I N A L A R T I C L E Contribution of Visceral Adiposity to the Exaggerated Postprandial Lipemia of Men With Impaired Glucose Tolerance PATRICIA BLACKBURN, MSC 1 BENOÎT
More informationISCHEMIC HEART DISEASE: Role of Total Cholesterol: HDL C Ratio as an Important Indicator Compared to LDL C.
International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 14, Number 1 (2018) pp. 13-17 Research India Publications http://www.ripublication.com ISCHEMIC HEART DISEASE: Role of Total
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationRole of Small Dense Low-Density Lipoprotein in Coronary Artery Disease Patients With Normal Plasma Cholesterol Levels. Small Dense KATAGIRI, MD, FJCC
J Cardiol 2000 ; 36: 371 378 Small Dense Role of Small Dense Low-Density Lipoprotein in Coronary Artery Disease Patients With Normal Plasma Cholesterol Levels Shinji Tsutomu Taro Keiko Takeshi Minoru Hiroshi
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationRaising high-density lipoprotein cholesterol: where are we now?
European Heart Journal Supplements (23) 5 (Supplement D), D17 D25 Raising high-density lipoprotein cholesterol: where are we now? Baylor College of Medicine, Houston, Texas, U.S.A. KEYWORDS Apolipoprotein;
More informationFriedewald formula. ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5. Friedewald formula. Friedewald formula
Friedewald formula 1 1 1,2 ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5 Friedewald formula Friedewald formula 2003 99 Friedewald formula Colorimetric method
More informationNorth Americans consume 100 g of fat per day on
PRACTICE AT THE BEDSIDE Common problems in the management of hypertriglyceridemia Michelle A. Fung, Jiri J. Frohlich Case A 41-year-old man presents for assessment of severe hypertriglyceridemia. He has
More informationORIGINAL INVESTIGATION. Low Triglycerides High High-Density Lipoprotein Cholesterol and Risk of Ischemic Heart Disease
ORIGINAL INVESTIGATION Low Triglycerides High High-Density Lipoprotein Cholesterol and Risk of Ischemic Heart Disease Jørgen Jeppesen, MD; Hans Ole Hein, MD; Poul Suadicani, DD; Finn Gyntelberg, MD Background:
More informationMetabolism and Atherogenic Properties of LDL
Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal
More informationLIPOPROTEIN PROFILING
LIPOPROTEIN PROFILING in CLINICAL DIAGNOSTICS and LIFE SCIENCE RESEARCH Product Information, March 2015 2004-2015, numares HEALTH LIPOPROTEINS AND CARDIOVASCULAR DISEASE High blood cholesterol is a well-known
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationStudy of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases
Original article: Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases Dr Abhijit Nikam, Dr Sonu Yadav, Dr Vivek Chiddarwar, Dr A L Kakrani Dept of Medicine,
More informationHigh-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.17 High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationInflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study
Atherosclerosis 182 (2005) 315 321 Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study Annie C. St-Pierre a,b, Bernard Cantin
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationThe Metabolic Syndrome Prof. Jean-Pierre Després
The Metabolic Syndrome 1 Jean-Pierre Després, Ph.D., FAHA, FIAS Quebec Heart and Lung Institute Department of Medicine Université Laval Québec, Canada Reaven s syndrome X Triglycerides HDL cholesterol
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationMeasurement of Small Dense Low-density Lipoprotein Particles
67 Journal of Atherosclerosis and Thrombosis Reviews Vol. 12, No. 2 Measurement of Small Dense Low-density Lipoprotein Particles Tsutomu Hirano 1, Yasuki Ito 2, and Gen Yoshino 3 1 Division of Diabetes
More informationComparison of two assays for measuring LDL cholesterol
Clinical Chemistry 43:6 1040 1047 (1997) Lipids and Lipoproteins Comparison of two assays for measuring LDL cholesterol Anirban Maitra, Shaina V. Hirany, and Ishwarlal Jialal* The purpose of this study
More informationApplicability of Cholesterol-Lowering Primary Prevention Trials to a General Population
Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph
More informationThe Second Report of the Expert Panel on Detection,
Blood Cholesterol Screening Influence of State on Cholesterol Results and Management Decisions Steven R. Craig, MD, Rupal V. Amin, MD, Daniel W. Russell, PhD, Norman F. Paradise, PhD OBJECTIVE: To compare
More informationApplication of New Cholesterol Guidelines to a Population-Based Sample
The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,
More informationApplication of New Cholesterol Guidelines to a Population-Based Sample
The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,
More informationORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease
ORIGINAL INVESTIGATION Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease Lynn E. Eberly, PhD; Jeremiah Stamler, MD; James D. Neaton, PhD; for the Multiple
More informationClinical Significance of Small Dense Low-Density Lipoprotein Cholesterol Levels Determined by the Simple Precipitation Method
Clinical Significance of Small Dense Low-Density Lipoprotein Cholesterol Levels Determined by the Simple Precipitation Method Tsutomu Hirano, Yasuki Ito, Shinji Koba, Miwako Toyoda, Ayako Ikejiri, Haruhisa
More informationStudy of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease
Original article: Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Dr Sonu Yadav, Dr Abhijit Nikam, Dr Vivek Chiddarwar, Dr A L Kakrani Department of Medicine,
More informationBiomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease
Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationLDL SUBCLASS PATTERNS AND ATHEROGENICITY IN NON-INSULIN DEPENDENT DIABETES MELLITUS
LDL SUBCLASS PATTERNS AND ATHEROGENICITY IN NON-INSULIN DEPENDENT DIABETES MELLITUS F. Kazerouni *1, E. Javadi 1, M. Doosti 1 and B. Larijani 2 1) Department of Medical Biochemistry, School of Medicine,
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationthe U.S. population, have some form of cardiovascular disease. Each year, approximately 6 million hospitalizations
Cardioprotection: What is it? Who needs it? William B. Kannel, MD, MPH From the Department of Preventive Medicine and Epidemiology, Evans Department of Clinical Research, Boston University School of Medicine,
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Measurement of Small Low Density Lipoprotein Particles sad EFFECTIVE DATE: 02 16 2010 POLICY LAST UPDATED: 10 15 2013 OVERVIEW Lipoprotein-associated phospholipase A2 (Lp-PLA2),
More informationC-REACTIVE PROTEIN AND LDL CHOLESTEROL FOR PREDICTING CARDIOVASCULAR EVENTS
COMPARISON OF C-REACTIVE PROTEIN AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN THE PREDICTION OF FIRST CARDIOVASCULAR EVENTS PAUL M. RIDKER, M.D., NADER RIFAI, PH.D., LYNDA ROSE, M.S., JULIE E. BURING,
More informationCLINICAL SCIENCE. Protasio Lemos da Luz, I Desiderio Favarato, I Jose Rocha Faria-Neto Junior, II Pedro Lemos, I Antonio Carlos Palandri Chagas I
CLINICS 2008;64:427-32 CLINICAL SCIENCE High ratio of triglycerides to hdlcholesterol predicts extensive coronary disease Protasio Lemos da Luz, I Desiderio Favarato, I Jose Rocha Faria-Neto Junior, II
More informationREAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More informationjournal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract
The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,
More informationAlthough the prevalence and incidence of type 2 diabetes mellitus
n clinical n Validating the Framingham Offspring Study Equations for Predicting Incident Diabetes Mellitus Gregory A. Nichols, PhD; and Jonathan B. Brown, PhD, MPP Background: Investigators from the Framingham
More informationPattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus
Original Article Nepal Med Coll J 2012; 14(4): 278-282 Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus A
More informationClinical Investigation and Reports
Clinical Investigation and Reports Effect of 7-Year Infancy-Onset Dietary on Serum Lipoproteins and Lipoprotein Subclasses in Healthy Children in the Prospective, Randomized Special Turku coronary Risk
More informationMetabolic control and serum lipid changes in diabetic Iraqi men
www.muthjm.com Muthanna Medical Journal 2017; 4(2):56-61 Metabolic control and serum lipid changes in diabetic Iraqi men Aqeel Raheem Hassan 1* Abstract The objective of this study is to demonstrate the
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationMedical - Clinical Research & Reviews
Research Article Research Article Medical - Clinical Research & Reviews ISSN 2575-6087 Association of BMI and Waist to Hip Ratio with the Ratio of LDL to HDL and Total Cholesterol to HDL in Urban Adolescents
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationRosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 3 Number 1 Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia V Save, N Patil, G Rajadhyaksha Citation V Save,
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationThe Framingham Risk Score (FRS) is widely recommended
C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany Wolfgang Koenig, MD; Hannelore
More informationDiabetes Care 31: , 2008
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S. KHIET C. HOANG, MD HELI GHANDEHARI VICTOR
More informationTraitements associés chez l hypertendu: Statines, Aspirine
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact
More informationEffects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease.
Michael Garshick, MD PGY-1 Columbia University Medical Center Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease. Study Purpose and Rationale:
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationChapter (5) Etiology of Low HDL- Cholesterol
Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationNovel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
Page: 1 of 35 Last Review Status/Date: December 2014 Management of Cardiovascular Disease Description Numerous lipid and nonlipid biomarkers have been proposed as potential risk markers for cardiovascular
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationWhen Do We Treat Hypercholesterolemia?
Clin. Cardiol. 15 (Suppl. In>, 111-10-111-14 (1992) When Do We Treat Hypercholesterolemia? w. VIRGIL BROWN, M.D. Department of Medicine, Emory University, Atlanta, Georgia, USA Summary: Although the relationships
More informationImproving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B The Copenhagen City Heart Study
Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B The Copenhagen City Heart Study Marianne Benn, Børge G. Nordestgaard, Gorm Boje Jensen, Anne Tybjærg-Hansen
More informationCoverage Guidelines. NMR LipoProfile and NMR LipoProfile -II Tests
Coverage Guidelines NMR LipoProfile and NMR LipoProfile -II Tests Disclaimer: Please note that Baptist Health Plan updates Coverage Guidelines throughout the year. A printed version may not be most up
More informationGUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES
GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES Prepared by DCPNS Action Committee Dr. Lynne Harrigan Brenda Cook Peggy Dunbar Bev Harpell with the assistance
More informationGlobal Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH
Diabetes Care Publish Ahead of Print, published online April 1, 2008 Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic Syndrome Khiet C. Hoang MD, Heli Ghandehari, BS, Victor
More informationPrevalence of High C-Reactive Protein in Persons with Serum Lipid Concentrations within Recommended Values
Papers in Press. First published June 17, 2004 as doi:10.1373/clinchem.2004.036004 Clinical Chemistry 50:9 000 000 (2004) Lipids, Lipoproteins, and Cardiovascular Risk Factors Prevalence of High C-Reactive
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationThe Association of Apolipoprotein B and Low Density Lipoprotein with Cardiovascular Risk Factors in the Thai Population
The Association of Apolipoprotein B and Low Density Lipoprotein with Cardiovascular Risk Factors in the Thai Population Rungroj Krittayaphong MD*, Chunhakasem Chotinaiwatarakul MD**, Charuwan Kangkagate
More informationPage 1. Disclosures. Background. No disclosures
Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen
More informationEffect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial
European Heart Journal (2003) 24, 1843 1847 ARTICLE IN PRESS Clinical research Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo
More informationNovel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
Page: 1 of 34 Last Review Status/Date: March 2016 Management of Cardiovascular Disease Description Numerous lipid and nonlipid biomarkers have been proposed as potential risk markers for cardiovascular
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationDownloaded from ijdld.tums.ac.ir at 19:13 IRDT on Friday May 4th 2018
- : -. : - 3 *. () - :.. 30 608 43 : (LDL-C) (HDL-C) TG/HDL-)HDL-C TG (TC/HDL-C)HDL-C (HRs) TC (non- HDL-C) (TG) (TC) HDL. 8/4. HR. ( 98 9). TG/HDL-C (C 89 : HDL-C.[/3 (/0 -/57)] TC/HDL-C. ( C ) WHO non-hdl-
More informationFibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit
Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.
More information